Jingwen Long
Shanghai Jiao Tong University(CN)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Lung Cancer Treatments and Mutations, Hepatocellular Carcinoma Treatment and Prognosis, Epilepsy research and treatment, Balance, Gait, and Falls Prevention
Most-Cited Works
- → Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy(2014)151 cited
- → Reference value for the TUGT in healthy older people: A systematic review and meta-analysis(2019)29 cited
- → Applying machine learning methods to develop a successful aging maintenance prediction model based on physical fitness tests(2020)26 cited
- → Abstract 2089: Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models(2017)7 cited
- → Abstract 4187: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF1R kinases(2017)5 cited
- → Abstract 4499: HM5016699, a novel and selective PI3K/mTOR dual inhibitor(2011)
- → Bioequivalence and Safety of Levetiracetam Granules and Oral Solution: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under a Fasting Condition(2022)
- → Abstract 1808: HM-032, a novel PI3K/mTOR dual inhibitor, is active on K-Ras/Raf mutation tumors through up-regulation of Bim(2012)
- → Experimenting with artificial neural networks-artificial intelligence mini-tutorial. 3(2003)
- → CSD 2092760: Experimental Crystal Structure Determination(2022)